Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea

  • Choi, Eun-Hwa (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Kim, Kyung-Hyo (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Kim, Yae-Jean (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Kim, Jong-Hyun (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Park, Su-Eun (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Lee, Hoan-Jong (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Eun, Byung-Wook (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Jo, Dae-Sun (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Choi, Kyong-Min (The Committee on Infectious Diseases, the Korean Pediatric Society) ;
  • Hong, Young-Jin (The Committee on Infectious Diseases, the Korean Pediatric Society)
  • Received : 2011.03.28
  • Accepted : 2011.04.15
  • Published : 2011.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Streptococcus pneumoniae remains a leading cause of invasive infections including bacteremia and meningitis, as well as mucosal infections such as otitis media and pneumonia among children and adults. The 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use among infants and young children in many countries including Korea. The routine use of PCV7 has resulted in a decreased incidence of invasive pneumococcal disease (IPD) by the vaccine serotypes among the vaccinees and substantial declines in IPD among unvaccinated populations such as older children and adults as well. In addition, there are increasing evidences to suggest that routine immunization with PCV7 is changing the epidemiology of pneumococcal diseases such as serotype distribution of IPD, nasopharyngeal colonization, and antibiotic resistance patterns. In contrast, there is an increase in the number of IPDs caused by nonvaccine serotypes, though it is much smaller than overall declines of vaccine serotype diseases. Several vaccines containing additional serotypes have been developed and tested clinically in order to expand the range of serotypes of Streptococcus pneumoniae. Recently two new pneumococcal protein conjugate vaccines, 10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13), have been approved for use in several countries including Korea. This report summarizes the recommendations approved by the Committee on Infectious Diseases, the Korean Pediatric Society.

Keywords

References

  1. The Korean Pediatric Society. Pneumococcal vaccine. In: Lee HJ, editor. Immunization Guideline. 6th ed. Seoul: The Korean Pediatric Society, 2008;196-216.
  2. Dagan R, Jacobs MR, Greenberg D. Pneumococcal infections. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan S, editors. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: WB Saunders, 2004;1204-58.
  3. Lee JH, Cho HK, Kim KH, Kim CH, Kim DS, Kim KN, et al. Etiology of invasive bacterial infections in immunocompetent children in Korea (1996-2005): A retrospective multicenter study. J Korean Med Sci 2011;26:174-83. https://doi.org/10.3346/jkms.2011.26.2.174
  4. Kim SH, Song EK, Lee JH, Kim NH, Lee JA, Choi EH, et al. Changes of serotype distribution of Streptococcus pneumoniae isolated from children in Korea over a 15 year-period (1991-2005). Korean J Pediatr Infect Dis 2006;13:89-98.
  5. Lee TJ, Chun JK, Choi KM, Yong DE, Lee KW, Kim DS. Trends in serotype distribution of clinical isolates of Streptococcus pneumoniae : a single center experience from 2001 to 2006. Korean J Pediatr Infect Dis 2006;13:115-23.
  6. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee HJ, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-81. https://doi.org/10.3201/eid1402.070807
  7. Korean Centers for Disease Control and Prevention. Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae clinical isolates in Korea. Public Health Wkly Rep 2010;3:1-7.
  8. World Health Organization. Technical Report Series, No. 927, Annex 2. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, 2009.
  9. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al. Immunogenicity of the 10-Valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) vompared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 Suppl):S66-S76.
  10. Food and Drug Administration. Prevnar 13: clinical review of new product license application. Rockville, MD: Food and Drug Administration, 2010.
  11. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and nontypeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006;367:740-8. https://doi.org/10.1016/S0140-6736(06)68304-9
  12. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010;59:258-61.
  13. Nuorti JP, Whitney CG;Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children-Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 2010;59(RR-11):1-18.

Cited by

  1. Cross-reaction of 6B and 19F Specific Antibodies to Serotypes 6A, 6C, and 19A after Immunization with 7-valent Pneumococcal Conjugate Vaccine in Korean Children Aged 12-23 Months vol.20, pp.2, 2011, https://doi.org/10.14776/kjpid.2013.20.2.53
  2. The Association between Asthma and Invasive Pneumococcal Disease: A Nationwide Study in Korea vol.30, pp.1, 2011, https://doi.org/10.3346/jkms.2015.30.1.60
  3. Changes in pneumococcal nasopharyngeal colonization among children with respiratory tract infections before and after use of the two new extended-valency pneumococcal conjugated vaccines vol.47, pp.6, 2011, https://doi.org/10.3109/00365548.2014.1001997
  4. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea vol.14, pp.1, 2011, https://doi.org/10.1080/21645515.2017.1362513
  5. A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea vol.14, pp.12, 2011, https://doi.org/10.1080/21645515.2018.1502525
  6. Why are people with asthma susceptible to pneumonia? A review of factors related to upper airway bacteria vol.24, pp.5, 2011, https://doi.org/10.1111/resp.13528
  7. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation vol.18, pp.6, 2011, https://doi.org/10.1080/14760584.2019.1627207
  8. The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma vol.17, pp.5, 2011, https://doi.org/10.15690/pf.v17i5.2187